IMRX vs. QNCX, RPID, ADAG, ASRT, IXHL, ATHA, RLMD, VXRT, KPTI, and IVA
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Quince Therapeutics (QNCX), Rapid Micro Biosystems (RPID), Adagene (ADAG), Assertio (ASRT), Incannex Healthcare (IXHL), Athira Pharma (ATHA), Relmada Therapeutics (RLMD), Vaxart (VXRT), Karyopharm Therapeutics (KPTI), and Inventiva (IVA). These companies are all part of the "medical" sector.
Quince Therapeutics (NASDAQ:QNCX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
Immuneering received 24 more outperform votes than Quince Therapeutics when rated by MarketBeat users.
In the previous week, Immuneering had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 3 mentions for Immuneering and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.96 beat Immuneering's score of 0.94 indicating that Immuneering is being referred to more favorably in the news media.
Immuneering's return on equity of -36.72% beat Quince Therapeutics' return on equity.
30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by insiders. Comparatively, 25.0% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Quince Therapeutics has higher earnings, but lower revenue than Immuneering. Quince Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.
Quince Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.61, suggesting that its stock price is 161% less volatile than the S&P 500.
Immuneering has a consensus price target of $13.50, suggesting a potential upside of 988.71%. Given Quince Therapeutics' higher probable upside, analysts plainly believe Immuneering is more favorable than Quince Therapeutics.
Summary
Immuneering beats Quince Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
Free IMRX Stock Alerts